Plain-English translation of NCT03866382 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three drugs: cabozantinib (a targeted therapy that blocks cancer growth), (an immunotherapy that helps your immune system fight cancer), and (another immunotherapy that works differently to boost your immune response). The study aims to see if this three-drug combination can help people with rare, advanced cancers of the bladder, kidneys, penis, prostate, or testicles—cancers that have spread to other parts of the body and for which there are fewer proven treatment options.
Many people with rare types of genitourinary cancer don't have standard, proven treatments available. This medication combination has shown promise in other cancer types, so researchers want to test whether it can offer real benefit for patients with these less common, harder-to-treat cancers.
You likely qualify if…
You likely don't qualify if…
You would take a pill form of one medication daily at home and receive two other medications through IV infusions on the first day of each treatment cycle. For the first four cycles (about 3 weeks each), you'll visit the clinic every 3 weeks; after that, cycles last 4 weeks. Throughout the trial—which lasts up to 2 years—you'll have regular blood tests, imaging scans (CT or MRI), and sometimes bone scans or PET scans to monitor how well the treatment is working. Your doctor will watch carefully for any side effects and adjust your treatment if needed.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
United States